Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Current Assets (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Current Assets for 15 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 65.15% year-over-year to $4.7 million, compared with a TTM value of $4.7 million through Sep 2025, down 65.15%, and an annual FY2024 reading of $11.1 million, down 2.16% over the prior year.
  • Current Assets was $4.7 million for Q3 2025 at BioRestorative Therapies, down from $7.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $21.5 million in Q4 2021 and bottomed at $1.2 million in Q3 2021.
  • Average Current Assets over 5 years is $11.8 million, with a median of $12.6 million recorded in 2023.
  • The sharpest move saw Current Assets soared 4794.93% in 2021, then tumbled 65.15% in 2025.
  • Year by year, Current Assets stood at $21.5 million in 2021, then decreased by 29.53% to $15.1 million in 2022, then dropped by 24.71% to $11.4 million in 2023, then decreased by 2.16% to $11.1 million in 2024, then tumbled by 57.76% to $4.7 million in 2025.
  • Business Quant data shows Current Assets for BRTX at $4.7 million in Q3 2025, $7.6 million in Q2 2025, and $9.4 million in Q1 2025.